Atosiban Acetate cas no 90779-69-4
This project falls into four categories of chemical drugs. It is an oxytocin antagonist. It is used for women over 18 years old and 24 ~ 33 weeks of gestation to delay their premature birth. Our company's atoxicillin acetate has a mature process route, with good process reproducibility and stable product quality.
As the only uterine contraction inhibitor with uterine specificity approved by the European Drug Administration for the treatment of premature birth, its mechanism of action is to compete with oxytocin for oxytocin receptors on the myometrium, decidua and fetal membranes, reduce the efficacy of oxytocin, reduce the level of calcium ions on muscle cells, and thus inhibit uterine contraction. Its advantage is that it has a good fetal protection effect, and long-term use will not change the sensitivity of the myometrium to oxytocin, It has high safety for mother and fetus, especially for pregnant women with threatened preterm birth whose curative effect of magnesium sulfate is not obvious, and it can also be used with ritodrine or magnesium sulfate.
It was first reported in 1987 that it would change the sensitivity of uterine myometrium to oxytocin. Since then, in 1995, 1996 and 2001, many international centers have reported that the effect is similar to that of adrenaline β Receptor agonists are similar, with side effects of about 5%, mainly digestive symptoms.
1. It is the only oxytocin antagonist with uterine specificity, focusing on anti premature delivery.
2. Compared to β The receptor agonist ritodrine had no adverse reaction of tachycardia.
3. It is especially suitable for pregnant women with heart disease and multiple pregnancies.
4. It is convenient for clinical use without dose adjustment.
Audited Supplier 
){kind=link}
){kind=link}